Key Highlights
• PM shares rose 1.35% today to $180.09, outperforming the broader market and consumer staples sector.
• The FDA issued Modified Risk Tobacco Product orders for 20 ZYN nicotine pouch variants.
• This marks the first MRTP authorization ever granted for nicotine pouches.
• The ruling allows PMI to market ZYN as reducing risk of several smoking-related diseases relative to cigarettes.
• A securities research firm raised its price target to $182 from $168.
FDA Grants First-Ever Nicotine Pouch Risk Reduction Claim
Philip Morris International Inc. (NYSE:PM) shares traded higher today after the U.S. Food and Drug Administration issued Modified Risk Tobacco Product orders for 20 variants of the company's ZYN nicotine pouch products. The Stamford, Connecticut-headquartered tobacco company sells its products in over 180 countries, with a strategic focus on smoke-free alternatives to cigarettes.
The ruling marks the first-ever MRTP authorization granted for any nicotine pouch product, allowing PMI to market ZYN with the claim that using the product instead of cigarettes puts consumers at lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.
Ruling Strengthens Smoke-Free Product Narrative Ahead of Earnings
The authorization materially strengthens PMI's smoke-free product narrative ahead of its second-quarter 2026 earnings report scheduled for July 22. A securities research firm raised its price target on the stock to $182 from $168 while maintaining a Neutral rating following the announcement.
Analysts carry a Moderate Buy consensus on the stock with an average price target range of $192.88 to $196. Company figures show smoke-free products accounted for approximately 39-43% of net revenues in recent periods, with the company having invested over $16 billion in smoke-free product development since 2008.
Conclusion
Philip Morris International's gain reflects investor recognition of the FDA's landmark decision to authorize reduced-risk marketing claims for ZYN nicotine pouches, reinforcing the company's smoke-free transformation strategy. With second-quarter earnings due July 22, the ruling adds a positive catalyst as the company continues to shift its revenue mix away from traditional cigarettes.
This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.






Please wait processing your request...